ABSTRACT Cell-surface-localized receptors and their extracellular ligands usually comprise distinct families and promote diversity of signal transduction regulation. The number of available ligand molecules is often the limiting factor for receptor activation during interpretation of the signal by the responding cell. Limited ligand availability in a particular area of tissue should lead to local competition between different members of a receptor family for binding and subsequent activation. Fibroblast growth factor receptor (FGFR) 4 (FGFR4) is a less potent activator of downstream pathways than FGFR1, the major subtype of FGFR. Regional expression of Xenopus FGFR1 and FGFR4 (XFGFR1 and XFGFR4, respectively) overlap in the anterior part of prospective and developing neural tissue. In this paper we show that XFGFR1 and XFGFR4 have opposing effects on the positioning of expression domains of mid-and hindbrain markers when the expression levels of the receptors are altered. We present a line of evidence to support our hypothesis that competition between XFGFR1 and XFGFR4 for ligands is required for correct positioning of marker expression. Local competition between receptors with different potencies should provide an efficient means for a cell to interpret the ligand signal correctly, and may constitute a more general mechanism for regulating signal transduction.
Introduction
The binding of exracellular ligands to cell-surface-localized receptors initiates intracellular signaling in the target cell, which triggers cellular activities such as cell division, cell differentiation and cell movements. The diversity of receptor and ligand families enables the formation of various ligand-receptor combinations. Clarifying the mechanisms involved in cooperation among these factors is essential to understanding developmental regulation in vivo and for clinical applications.
Fibroblast growth factors (FGFs) and their receptors (FGFRs) constitute one of the major signal reception systems important for embryonic development and adult homeostasis. Four distinct FGFR genes (FGFR1 to FGFR4) are present in vertebrates and encode four receptor protein subtypes (Dailey et al., 2005; Eswarakumar and Schlessinger, 2005) . The four FGFR genes are expressed in a range of embryonic and adult tissues in distinct but often partly overlapping patterns (Thisse et al., 1995; Hughes 1997; Hongo et al. 1999; Golub et al. 2000; Yaylaoglu et al., 2005; Lunn et al., 2007) . Each FGFR subtype comprises an FGFbinding extracellular domain (ECD), a catalytic intracellular domain (ICD), and a short transmembrane domain spanning them. Ligand binding causes FGFRs to dimerize via the ECD, and the dimerization is followed by phosphorylation of the ICD kinase domain and downstream signaling. The Ras pathway, the phosphatidylinositol-3 kinase (PI3K) pathway and the phospholipase Cγ (PLCγ) pathway are the major signaling cascades downstream of FGFR activation.
The signaling properties of different FGFR/FGF combinations have been compared biochemically in several studies that used cultured cells (Vainikka et al., 1994; Wang, J.-K. et al., 1994; Shauol et al., 1995; Ornitz et al., 1996; Raffioni et al., 1999) . Since those studies showed that all FGFR subtypes have similar intracellular signaling properties, the major difference in functions of the receptor ICDs may be quantitative rather than qualitative and reflect the varying strengths of kinase activity required to activate common downstream pathways (Raffioni et al., 1999; Dailey et al., 2005) . FGFR1 exhibits the strongest kinase activity and FGFR4 exhibits the weakest. Although possible qualitative differences in intracellular signaling events downstream of different FGFRs cannot be excluded based on current evidence, it seems likely that the diverse biological responses elicited by FGF binding arise largely from the different cellular contexts (Dailey et al., 2005) .
The present study examined the functional roles of Xenopus FGFR1 and FGFR4 (XFGFR1 and XFGFR4, respectively) in early neural development. We found that the correct positioning of regional neural marker expression in Xenopus depends on the expression levels of XFGFR1 and XFGFR4. We then show that local competition between XFGFR1 and XFGFR4 for ligand binding provides a consistent explanation for the mechanism underlying this regulation. Such receptor competition may enable a cell to efficiently interpret the ligand signal.
Results

Differential expression of XFGFR1 and XFGFR4 is important for correct early neural development
In the gastrula stage, strong XFGFR4 expression is restricted to the anterior region, whereas XFGFR1 is expressed broadly (Riou et al., 1996; Hongo et al., 1999; Golub et al., 2000) . RT-PCR analysis showed that differential expression in the dorsal region became apparent by stage 10 (Fig. 1A ) and persisted throughout gastrulation (not shown). Examination of a bisected embryo showed XFGFR1 mRNA distributed over the ectoderm and mesoderm in the outer tissue (including the leading edge of the involuting mesoderm; Fig. 1 ,D left), whereas XFGFR4 mRNA was abundant within and anterior to the prospective midbrain-hindbrain boundary (MHB), which was marked by expression of the early MHB marker, XHR1 (Shinga et al., 2001) (Fig. 1D right,E) .
To assess the significance of the XFGFR1 and XFGFR4 expression levels for early Xenopus development, we unilaterally injected the prospective anterior neural region of embryos with the respective mRNAs (for overexpression) or morpholino antisense oligonucleotides (MOs) (for underexpression). Up-or down-regulation of FGF signaling in the marginal zone of early embryos impairs gastrulation by causing abnormal mesoderm development (Amaya et al., 1991; Thompson and Slack, 1992; Kroll and Amaya, 1996) and affects the shaping of neural structures during subsequent development. To prevent such defects, care was taken to accurately target the injections (Fig. 2A) . After in situ hybridization for the MHB marker Xpax2 (Heller and Brandli, 1997) , embryos that did not express nLacZ (a co-injected linear tracer) in areas anterior to the Xpax2-expressing region were excluded from the analysis.
Injection of XFGFR1 mRNA caused an anterior shift in Xpax2 expression on the injected side (Fig. 2B left,L line 2). In some injected embryos, only the lateral edge of the Xpax2-expressing region was directed anteriorly ("smiling phenotype"), most likely due to lateral distribution of the injected mRNA ( Fig. 2B right,L line 2). By contrast, XFGFR4 mRNA caused a posterior shift in Xpax2
Injection of XFGFR1-MO shifted Xpax2 expression posteriorly, whereas XFGFR4-MO induced an anterior shift (Fig. 2 D,E,J,L lines 5 and 6). The phenotypes were mitigated or even reversed by coinjection with the rescue XFGFR mRNAs (Materials and Methods) with which antisense nucleotides do not hybridize (Fig. 2 F ,G,L lines 7 and 8). The same pattern shifts were observed in expression of the other MHB marker En2 and the hindbrain rhombomere 3 and 5 marker Krox20 by altering the XFGFR expression levels (data not shown). Thus, XFGFR1 and XFGFR4 showed opposing effects on marker expression when their expression levels were altered, demonstrating that the levels of expression of XFGFR1 and XFGFR4 are crucial for normal development of the neural region. A stage-11 embryo was sagitally bisected through the dorsal blastopore groove (arrowheads), and the halves were hybridized for XFGFR1 (left) or XFGFR4 (right). Dotted lines indicate the ectoderm/ mesoendoderm boundary. (E) A stage-11 embryo was sagitally bisected, and the halves were hybridized for XFGFR4 (left) or XHR1 (right). Before bisection, the dorsal side was flattened by gentle pressure to compare the distances between the posterior limits of the expression regions and the blastopore groove (arrowheads).
B C D E A FGFR1/4 competition during neural development 95
The extracellular domains of XFGFR1 and XFGFR4 are interchangeable with respect to effect on marker expression patterns To determine whether the difference in the affinities of XFGFRs for FGF ligands contributes to their opposing effects on marker expression, we constructed two chimeric FGFRs: XFGFR1/4 composed of the ECD of XFGFR1 (XFGFR1-ECD) and the ICD of XFGFR4 (XFGFR4-ICD), and XFGFR4/1 with the opposite domain combination (Fig. 2K) . Injection of these chimera mRNAs clearly showed that the ECDs of XFGFR1 and XFGFR4 are interchangeable: XFGFR1/4 shifted Xpax2 expression posteriorly and XFGFR4/1 shifted it anteriorly (Fig. 2 H,I ,L lines 11 and 12). This finding was somewhat unexpected in light of the different affinities of FGFs for different FGFRs. The strong link between the subtypes of the ICDs and the direction of the shift induced indicated that the total signal inputs at the ECDs of these two receptors are comparable in this region of the embryo and that the difference in signal outputs from the ICDs drives the marker shifting.
XFGFR1 and XFGFR4 competition for ligands acts as the regulatory mechanism
What is the mechanism underlying the opposing effects of XFGFR1 and XFGFR4 in directing Xpax2 expression? We separated the process of receptor activation from that of ligand reception by using constitutively active (ca) forms of XFGFR1 and Fig. 3A, 4N ). If the opposing effects simply arose from qualitative difference in the properties of the intracellular pathways downstream of XFGFR1 and XFGFR4, caXFGFR1 and caXFGFR4 should also show the opposing effects. However, both caXFGFRs shifted Xpax2 expression anteriorly, with caXFGFR4 only conferring the phenotype at a higher dose (Fig.  4 A,B,O lines 1 and 2). Varying the dose of caXFGFR4 mRNA changed the frequency of marker shifting but not the direction of the shift (not shown). The results with the ligand-independent activated ICDs demonstrated that the intrinsic activities of the XFGFR1-ICD and XFGFR4-ICD are qualitatively indistinguishable with respect to effects on the direction of the shift in Xpax2 expression (i.e., shifting it anteriorly). The weaker shifting activity of XFGFR4-ICD is consistent with the notion that FGFR4-ICD is less potent than FGFR1-ICD as an activator of downstream pathways (Raffioni et al., 1999; Dailey et al., 2005) . The absence of opposing signaling effects by the caXFGFRs excluded the possibility that intracellular signaling events downstream of FGFRs determine the specificity of the direction of shifting. The requirement for intact ECDs in order for the opposing effects to occur revealed that the process of ligand reception is involved in regulation of the wild-type receptors. If the two XFGFRs compete for limited amounts of common ligands, an imbalance in the amounts of the receptors should alter the positioning of marker expression in opposing ways: anterior shifting of marker vs. caXFGFR1/4; Fig. 4K lanes 1, 2, 7 and 8). ERK activation caused by caXFGFR1 mRNA and iXFGFR1 mRNA persisted in the presence of 3 fold the amounts of caXFGFR4 mRNA or iXFGFR4 mRNA, respectively ( Fig. 4K lane 5, L lane 12), corresponding that the direction specificity of marker shifting is not attributable to intracellular competition between the downstream pathways of XFGFR1 and XFGFR4. RT-PCR analyses in animal caps demonstrated a substantial difference in the abilities of XFGFR1-ICD and XFGFR4-ICD to express the mesodermal maker Xbra (Fig. 4M) . Xbra is known to be expressed through the Ras pathway and the PI3K pathway, the later pathway functioning downstream of Ras and in parallel with ERK in FGF signaling (Carballada et al., 2001) . Our results of ERK activation assay and Xbra expression assay reconfirmed that XFGFR4-ICD is less potent to activate the down-B A expression should be caused by higher-than-normal signaling levels (generated by XFGFR1 overexpression or XFGFR4-MO injection) and posterior shifting should be caused by lower-thannormal levels (generated by XFGFR4 overexpression or XFGFR1-MO injection). On the other hand, when ligand-independent signaling is generated, the signaling level should simply add to the endogenous level of FGF signaling, leading to anterior shifting irrespective of the ICD subtype. The results with caXFGFRs, whose ECDs are deficient with respect to FGF binding (Neilson and Friesel, 1995) , were highly consistent with this proposed receptor competition mechanism.
To verify that FGF-independent activated receptors shift Xpax2 expression anteriorly irrespective of the ICD subtype, we generated an additional set of altered XFGFRs by using the synthetic agent AP20187 (ARIAD) to induce FGFR dimerization/activation (Welm et al., 2002; Pownall et al., 2003) . The ICDs of XFGFR1 and XFGFR4 were inserted between the myristoylation signal sequence and the AP20187-binding region FKBP 36V to generate iXFGFR1 and iXFGFR4, respectively (Fig. 3B, 4N ). Both iXFGFRs shifted marker expression anteriorly in the presence of AP20187, although the efficiency of iXFGFR4 was very low (Fig. 4 E,F,O lanes 5 and 6).
Different activating potencies of XFGFR1-ICD and XFGFR4-ICD to activate ERK though the Ras pathway were confirmed in animal cap assays, which showed more robust activation by XFGFR1-ICD ( Fig. 4K lanes 1 and 2, L lanes 8 and 9). Note that the difference in ERK activation between caXFGFR1 and caXFGFR4 reflected the intrinsic properties of the ICDs rather than differences in the dimerization efficiency of the ECDs, since interchanging the ECDs of these receptors did not significantly affect ERK activation (caXFGFR1 vs. caXFGFR4/1; caXFGFR4 stream pathways than XFGFR1-ICD. A similar difference in the levels of Xbra expression was observed when the wild-type XFGFR1 and XFGFR4 were overexpressed in animal caps (not shown), indicating that the signaling property inherent to each of the ICDs of the wild-type receptors were maintained in ligandindependent receptor activation.
To determine whether any receptor activation factors other than those related to ligand availability (for example, potential cofactors for receptor dimerization) are limited, we overexpressed FGFs. A small amount of eFGF mRNA (Isaacs et al., 1992) or FGF8a mRNA (Christen and Slack, 1997; Fletcher et al., 2006) resulted in the 'smiling' phenotype (Fig. 4 G,H,O line 7 and 8) and a low incidence of the anterior shift phenotype that was clearly restricted to the side of the embryos injected, but 'smiling' Xpax2 expression was frequent on both sides of the embryos (Fig. 4H) . This size reduction of anterior neural structures observed on both injected and non-injected sides of embryos was thought to reflect the diffusive nature of FGFs (Christen and Slack, 1999; Fletcher et al., 2006) . Thus, our result with FGF overexpression is consistent with receptor competition for ligands, since if ligand availability alone is limited, an increase in the FGF level would cause such size reduction of the anterior structures if the FGF were able to bind to and activate at least one of the four receptor subtypes. When XFGFR4 mRNA was co-injected, the anterior reduction caused by FGF overexpression did not occur, and Xpax2 expression on the injected side was shifted posteriorly (Fig. 4 I ,J,O lines 9 and 10), indicating the importance of the balance between ligands and receptors in the positioning of marker expression. In this way, we confirmed that the positioning of marker expression is regulated by competition between XFGFR1 and XFGFR4 for ligands.
Fig. 3. Ligand-independent activation of the caXFGFRs (A) and iXFGFRs (B). (A)
The C337Y and C345Y amino acid substitutions confer constitutive activity on XFGFR1 and XFGFR4, respectively, by forming intermolecular disulfide bonds between the monomeric receptors. As a result of alterations to their immunoglobulin-like regions, the mutant receptors lose affinity for FGF ligands (Neilson and Friesel, 1995) and thereby lose their ability to compete with endogenous receptors for activation. (B) The ICDs of XFGFR1 and XFGFR4 were inserted between the myristoylation signal sequence and the AP20187-binding region, 2x FKBP36V-HA (yellow). Receptor dimerization/activation commences with the addition of AP20187. The structures of iXFGFR1 and iXFGFR4 are based on the mouse version of AP20187-inducible FGFR1 (Welm et al., 2002; Pownall et al., 2003) .
The shift in Xpax2 expression in response to altering Ras and PLCγ γ γ γ γ activation levels is consistent with the proposed receptor competition mechanism
If the positioning of marker expression was regulated by FGFR competition, the marker shift should also be observed when the activation levels of the intracellular pathways are altered. To look first at the Ras pathways, a constitutive mutation was introduced to XNras to generate the oncogenic caXNras. Injection of caXNras mRNA shifted the Xpax2-expression region anteriorly (Fig. 4O  line 11) , the same as injection of caXKi-ras mRNA (not shown). In contrast, a dominant-negative (dn) form of ras, dnRas (Deng and Karin, 1994) , induced a posterior shift in Xpax2-expression ( Fig.  4O line 12) . Thus, regulation of the Ras pathway is involved in the positioning of marker expression, and the direction of marker shifts is consistent with receptor competition as the mechanism that regulates the intensity of intracellular signaling.
The PLCγ pathway is also activated by FGFRs, although its activation by FGFR4 is weak (Vainikka et al., 1994) . To downregulate this pathway, we constructed mutant XFGFRs containing a tyrosine-to-phenylalanine substitution in the consensus YLDL sequence near the C-terminus, which abolishes direct activation of PLCγ by the wild-type receptor (Mohammadi et al., 1992; Vainikka et al., 1994) . The resulting XFGFR1 mutant form, XFGFR1 Y762F , was still capable of shifting the position of Xpax2 expression anteriorly (Fig. 4O line 13 ), but with significantly less efficiency (compare with Fig. 2L line 2) . A comparable substitution in XFGFR4 (XFGFR4Y 766F ) enhanced the ability of XFGFR4 to shift marker expression posteriorly ( Fig. 4O line 14 ; compare to Fig. 2L line 3) . The difference in the intrinsic abilities of XFGFR1 Y762F -ICD and XFGFR4Y 766F -ICD to shift Xpax2 expression anteriorly were evident when the mutant ICDs were activated in a AP20187-dependent manner (Fig. 4O lines 17 and 18) . Together, these results indicated that activation of the PLCγ pathway by XFGFs is also involved in the positioning of marker expression. We then investigated whether PLCγ itself is required for correct positioning of marker expression. An MO against use of ligand-independent receptor activation systems in investigating the outputs of the ICDs, and underscore the similarity in signaling processes downstream of XFGFR1 and XFGFR4.
Heterodimers between XFGFR1 and XFGFR4 are active in terms of signal transduction It has been suggested that different FGFR subtypes may heterodimerize in vivo (Bellot et al., 1991; Ueno et al., 1992) . If heterodimers between XFGFR1 and XFGFR4 were incapable of triggering signaling, each subtype receptor monomer would behave as a dominant-negative inhibitor of other subtypes. If that were true, the heterodimers would suppress signaling even in the presence of excess amounts of ligands. However, whether heterodimers between XFGFR1-ICD and XFGFR4-ICD actually engage in signaling or are inactive complexes has not been determined. To examine this, we used dimerization system in which two different protein molecules are assembled via AP21967 (Fig.  5 ). XFGFR1-ICD and XFGFR4-ICD were fused to an AP21967-binding site, FKBP, to yield iXFGFR1k and XFGFR4k, respectively, or fused to another AP21967-binding site, FRB 2098L , to yield iXFGFR1r and XFGFR4r, respectively (Fig. 6A) . Since AP21967 forms a bridge between FKBP and FRB 2098L , only heterodimers or homodimers of the XFGFR ICDs could be formed in embryos injected with an appropriate combination of mRNAs Xenopus PLCγ1 (XPLCγ1-MO) induced an efficient posterior shift in Xpax2-expression ( Fig. 4O line 20) , and its effect was rescued by injection of XPLCγ1 mRNA ( Fig. 4O line 21) . The above findings show that the Ras pathway and the PLCγ pathway contribute to the positioning of marker expression. The effects of altering the activation levels of these pathways were consistent with what was expected as a consequence of our receptor competition hypothesis.
The findings on the PLCγ pathway also revealed that the degree of the relative contribution of the activation of this pathway by the wild-type XFGFRs to the positioning of marker expression was faithfully maintained when the ICDs were activated ligand-independently [ (Fig. 2L lines 2 Fig. 4M ), the findings validate the (Fig. 5) .
Both heterodimers (iXFGFR1k-iXFGFR4r and iXFGFR1r-iXFGFR4k) induced an anterior shift in Xpax2 expression (Fig. 6 B,C,G lines 5 and 6), albeit less efficiently than the iXFGFR1k-iXFGFR1r homodimers did (Fig. 6G line 7) . Neither anterior shift of Xpax2 expression (Fig. 6 E,G line 8) nor ERK activation in animal caps (Fig. 6F lane 9) was induced by iXFGFR4k-iXFGFR4r homodimers, indicating reduced dimerization capability of this system in comparison with the system that used AP20187. Consequently, the heterodimer activities were moderate in terms of ERK activation and marker shifting compared to the activities of the homodimerized XFGFR1-ICD and XFGFR4-ICD molecules. Although the efficiency of heterodimerization in vivo is unknown, it is very likely that total FGF signaling output would not differ much in the absence and presence of heterodimerization. We concluded that heterodimerization would not inhibit the intrinsic signaling activities of the ICDs of either receptor subtype.
Convergent extension as well as cell fate determination is likely to determine the positioning of marker expression downstream of receptor competition
Finally, we addressed the question of the cellular functions that define the positioning of marker expression as a consequence of receptor competition. It is well established that FGFs posteriorize neural tissues (Cox and Hemmati-Brivanlou, 1995; Kengaku and Okamoto, 1995; Pownall et al., 1996; McGrew, et al., 1997; Holowacz and Sokol, 1999; Hongo et al., 1999; Ribisi et al., 2000) , implicating fate determination as a regulatory factor. Increasing FGF signaling may confer more posterior fate to cells, shifting the neural marker expression anteriorly, while decreasing signaling would shift expression posteriorly.
In addition to cell fate determination, neural tissue development depends on extensive cell movements. Convergent extension is essential for tissue elongation along the anteroposterior axis, and is prominent only posterior to the MHB in neural ectoderm (Keller et al., 1992) , where XFGFR1 expression predominates over XFGFR4 expression (Fig. 1) . FGF signaling has been implicated in convergent extension (Nutt et al., 2001; Yokota et al., 2003; Aarmar and Frank, 2004) . Thus, when expression of XFGFR1 or XFGFR4 is altered toward increasing the output of FGFR signaling, the area of extensive tissue lengthening may expand into the anterior neural region, leading to an anterior shift in Xpax2 expression. Likewise, reducing the convergent extension by altering expression in the opposite way may shift the marker expression posteriorly.
To determine whether convergent 
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A extension plays a role in the positioning of Xpax2 expression, we examined the effects of up-and down-regulation of CDC42, whose activity is required for such movements (Djiane et al., 2000; Choi and Han, 2002) . caCDC42 was expressed under the control of the CMV promoter following the midblastula transition, since direct injection of caCDC42 mRNA impairs early embryonic cytokinesis (Drechsel et al., 1996; Djiane et al., 2000) . Xpax2 expression was shifted anteriorly by the caCDC42 plasmid ( Fig.  7 A,C line 1) with low efficiency, possibly in part due to unequal expression in DNA-injected embryos (for example, see Kroll and Amaya, 1996) . dnCDC42 mRNA, on the other hand, induced a posterior shift in Xpax2 expression (Fig. 7 B,C line 2) . Gain or loss of CDC42 activity has been found to inhibit proper convergent extension in whole embryos as well as in activin-treated animal caps (Djiane et al., 2000; Choi and Han, 2002) . In our experiments on anteriorly targeted expression, caCDC42 and dnCDC42 demonstrated opposing effects, indicating the involvement of convergent extension in marker expression positioning. The intrinsic elongation activities of XFGFR1-ICD and XFGFR4-ICD on neuralized animal caps were compared by adding AP20187 at stage 11.5, when competency for mesoderm formation had been lost (Pownall et al., 2003) . Elongation of noggin-expressing caps was induced by injection of iXFGFR1 mRNA, but little effect was observed with iXFGFR4 mRNA (Fig. 7 D,E) . This marked difference between the elongation abilities of iXFGFR1 and iXFGFR4 may account for the opposing effects of XFGFR1 and XFGFR4 on marker expression positioning.
It seems unlikely that the major outcome of the proposed receptor competition is manifested in the form of apoptosis, since neither the anti-apoptotic protein Bcl2 (Yeo and Gautier, 2003) nor the pro-apoptotic protein Bax affected the positioning of marker expression in mRNA injection experiments (not shown). However, temporally controlled apoptosis may be required for regulation of marker expression positioning.
Since the results of this study suggested that well-tuned convergent extension directed by FGF signaling regulates the normal positioning of marker expression, it is likely that cell movements as well as cell fate determination play roles, with both functioning downstream of the receptor competition.
Discussion
The confinement of expression of XFGFR4 to the anterior portion of prospective and developing neural region in Xenopus contrasts sharply with the broad distribution of XFGFR1 expression. The current study revealed an exquisitely balanced relationship between the expression profiles of these two receptor genes and normal early neural development, demonstrating coordinated actions of the receptors. We propose that receptor competition for ligands underlies this coordination by regulating the downstream pathways.
XFGFR1 and XFGFR4 compete for ligands to regulate downstream signaling during early neural development
The differential expression of XFGFR1 and XFGFR4 are evident by the early gastrula stage. Increasing or decreasing the level of expression of each receptor gene affects the anteroposterior positioning of regional neural marker expression. This observation was made possible by carefully targeted injection of reagents at doses low enough to avoid the gross gastrulation defects caused by impaired mesoderm development. The marker shift assay provided us with a sensitive means of identifying the molecules that affect the expression domains of the regional marker Xpax2. Notably, the assay showed that XFGFR1 and XFGFR4 have opposing effects, an anterior shifting effect by XFGFR1 and a posterior shifting effect by XFGFR4. We also found that the ECDs were interchangeable between XFGFR1 and XFGFR4 without changing the specificity in direction of shifting. Therefore, despite the existence of several FGF ligands in the developing anterior neural region, each with different affinities for the respective XFGFRs, the overall extracellular signal levels received by XFGFR1-ECD and XFGFR4-ECD were comparable, highlighting the large difference in the properties of the ICDs.
The opposing effects of XFGFR1 and XFGFR4 seen in the marker shift assays were lost when FGF signaling was activated ligand-independently. Both XFGFR1-ICD and XFGFR4-ICD induced anterior shifting, eliminating intracellular events downstream of the receptors as determinants of the opposing effects. Together with a marked quantitative difference between the potencies of FGFR1-ICD and FGFR4-ICD for activating downstream pathways, this observation strongly supports the hypothesis that competition for ligands occurs during receptor activation at the cell surface. No receptor activation factors other than those related to ligand availability are limited, as evidenced by the result with FGF overexpression; the size reduction of anterior neural structures both on injected and non-injected sides of the embryos, which reflects the diffusive nature of FGFs (Christen and Slack, 1999; Fletcher et al., 2006) . This phenotype was rescued by coexpression of XFGFR4. We conclude that ligand availability is limited in the developing anterior region.
Anterior ectodermal cells are rich in XFGFR4 mRNA and thereby should be less potent in signaling under ligand-limiting conditions than the posterior cells. Indeed, the region of low-level ERK activation (Schohl and Fagotto, 2002) coincided with the region of intense XFGFR4 expression. We speculate that autocrine FGFs and concomitant XFGFR4 expression are responsible for the weak signaling in this region.
Since the direction of the shift in marker expression caused by altering the Ras and PLCγ activation levels was consistent with the postulated receptor competition mechanism, both of these downstream pathways are likely to be involved in the XFGFRrelated positioning of marker expression. However, XFGFR1 Y762F , which has an amino acid substitution in the region required for interaction with PLCγ, maintained substantial anterior shifting activity for marker expression. Whether the Ras and PLCγ pathways function independently is unclear, because Ras-PLCγ crosstalk may occur (Pawson and Saxton, 1999) . It is possible that failure to directly activate this pathway by XFGFR may be partly compensated by Ras signaling.
The differential abilities of XFGFR1 and XFGFR4 to activate ERK (through the Ras pathway) and to induce Xbra expression (through the Ras and PI3K pathways) were confirmed for ca and iXFGFRs, and the relative effects of the PLCγ-binding mutations on marker shifting were virtually equivalent in XFGFR1 and XFGFR4. Though it is unlikely that the extent of the relative contribution of each downstream pathway to the positioning of marker expression is identical in XFGFR1 and XFGFR4 signaling, our results suggest that the qualitative properties of signaling elicited by the two XFGFRs are highly similar and that the quantitative difference in combined signaling levels of the intracellular pathways downstream of the two receptors is important for the positioning of marker expression. Umbhauer et al. (2000) used chimera receptors in which the XFGFR ICD is fused to the ECD of platelet-derived growth factor receptor or a mutant form of torso and found that XFGFR4 is incapable of activating RAS/ERK. However, FGFR4 has been shown to weakly but significantly activate ERK in other experimental systems (Vainikka et al., 1994; Shauol et al., 1995; Raffioni et al., 1999) . This discrepancy may reflect different efficiencies of receptor activation. It should be noted, however, that our results do not exclude possible qualitative differences between XFGFR1 and XFGFR4 in signaling properties crucial for other developmental processes. Nor do our results rule out intracellular competition between XFGFR1 and XFGFR4 signaling either where both signaling pathways are highly activated by abundant ligands or in certain cells that produce only limited amounts of common signaling components.
Cell fate determination and convergent extension as plausible cellular activities that determine the positioning of marker expression
The anterior shifting and posterior shifting of marker expression can be explained by posteriorization and anteriorization, respectively, of cell fate, which is determined by FGF signaling levels. In addition to being affected by cell fate determination, early neural development is substantially affected by cell move-ments, and marker expression patterns may also be regulated by morphogenetic processes. In fact, our marker shift assay of mutant forms of CDC42 demonstrated that convergent extension is involved in the positioning. Moreover, XFGFR1-ICD was more efficient than XFGFR4-ICD in elongating neuralized animal caps. These findings suggest that both cell fate determination and convergent extension determine the positioning of marker expression by the receptor competition mechanism. It is noteworthy that the pronounced extension of the developing Xenopus neural tissue is restricted posterior to the prospective midbrain and relatively little extension takes place in more-anterior regions (Keller et al., 1992) , where XFGFR4 expression is abundant.
When the expression levels of XFGFRs were altered, the location of Rx1 expression was less affected compared to that of Xpax2, En2 and Krox20 and no significant shift of Bf1 expression was observed (not shown). The marker shifting may occur only within the defined area of neural region, suggesting a more important role of cell movements for the phenotype. We were unable to test posterior makers, such as HoxB9, in marker shift assay since the injected site was not appropriate to examine their expression (shifting injection site towards the posterior led to gastrulation defects).
Competition between XFGFR1 and XFGFR4 as an efficient mechanism to maintain low FGF signaling
Ligand reception under locally restricted ligand-limiting conditions has been demonstrated in regard to several receptors (Hajnal et al., 1997; Gurdon and Bourillot 2001 ; and the references therein), with signaling events mediated by only one type of receptor. If related receptors sharing affinities for a common ligand(s) are coexpressed, a ligand-limiting state inevitably produces local receptor competition like the competition described here.
A hallmark of the competition between XFGFR1 and XFGFR4 described here is that the competing receptors elicit qualitatively similar but quantitatively different intracellular signaling. Furthermore, heterodimers between XFGFR1 and XFGFR4 are not defective forms but engage in signal transduction. Since the activation levels of heterodimers were intermediate between those of the homodimers in both the marker shift assay and the ERK assay, the intrinsic activities of the receptor ICDs are manifested irrespective of the heteroodimers/homodimers ratio. Once a ligand-limiting state disappears, the responding cell may virtually display the maximal signaling abilities of the ICDs. Therefore, the setting for competition between XFGFR1 and XFGFR4 is distinct from that for regulation of signaling-competent receptors by receptors lacking domains required for activation of the downstream pathways; the suppressive effects of these defective receptors on signaling events are invariant. For example, BAMBI, that is related to BMPR but kinase inactive, binds to type I BMP receptor (Onichtchouk et al., 1999) and thus would suppress BMP signaling even in the presence of saturating levels of ligands. Planarian Nou-darake (Cebria et al., 2002) and its Xenopus homologue XFGFRL1 (Hayashi et al., 2004) are FGFRrelated proteins lacking an intracellular kinase domain and thus should act like dnFGFR (Amaya et al., 1991) . Another example of a receptor lacking a kinase domain in its ICD is IGF2R. IGF2R reduces the level of circulating IGF2 by its ligand clearance activity, which decreases the activity of other IGF receptors (Lau et al., 1994; Wang, Z.-Q. et al., 1994; Ludwig et al., 1996) . By contrast, local competition for ligands between receptors with low or high signal transduction potency (like the competition between XFGFR1 and XFGFR4) is an efficient mechanism for maintaining low signaling levels, and yet cells are able to prime an immediate response to increased local ligand availability.
Since weak FGF signaling has been implicated in Xenopus neural induction (Hongo et al., 1999; Delaune et al., 2005) , it is highly likely that receptor competition in the prospective anterior region is also required for neural induction. The inhibitory effect of dnXFGFR4 in neural development (Hongo et al., 1999; Hardcastle et al., 2000; Kuroda et al., 2004; Delaune et al., 2005) may be explained by imbalanced receptor competition. At later stages of development, regional differentiation of neural tissue seems to proceed in response to increasing FGF levels from several local sources. Receptor competition may also be important for ERK activation triggered by wounding in the early embryos. Although conflicting observations have been made in regard to the FGFRdependency of this transient ERK activation (LaBonne and Whitman, 1997; Christen and Slack, 1999) , competing receptors can efficiently respond to FGFs (such as bFGF, which lacks the secreting signal sequence) released from injured cells.
Another feature of competition between receptors having different potencies is that the receptor with lower potency for activating downstream pathways moderates cell responsiveness to increasing concentrations of local ligand. Cells respond irreversibly to the highest concentration of ligand during the period of competency (Gurdon et al., 1995; Dyson and Gurdon, 1998) . Competition should ensure the correct choice of cell fate and behavior to counter fluctuating ligand concentrations.
A simple inference from the competition between XFGFR1 and XFGFR4 during early neural development is that competition for ligands may occur among all subtype FGFRs. FGFRs are often coexpressed in vertebrate tissues, and although it is evident that receptor-ligand specificity is primarily important in FGF signal transduction (Yu et al., 2000) , there are overlapping specificities in ligand affinities for the different subtype FGFRs (Eswarakumar and Schlessinger, 2005) . Receptor competition for ligands may therefore be involved in many other FGF signaling events where ligand availability is limiting.
Intuition suggests that local receptor competition in signaling may be integrated in various cellular systems, although no clear examples have been reported, perhaps because of the general difficulty in determining the nature of local ligand-receptor relationships where multiple ligands and receptors co-exist. The coordinated actions of XFGFR1 and XFGFR4 in the developing anterior region of Xenopus provide a simple ligand-receptor relationship in that the ligand-binding domains of the receptors are interchangeable with respect to effect on marker expression patterns. Another difficulty in identifying receptor competition is that competitive states in vivo cannot be easily reproduced in conventional cell culture systems; while ligand is available in restricted extracellular space in vivo, exogenous ligand is added to a large volume of medium in cell culture. Reducing the concentration of the ligand added in cell culture merely results in lower occupancy of each receptor by the ligand without any mutual influence among receptors during the limited time required for the interpretation of signal strength.
In conclusion, the results of the present study shed light on a potentially important aspect of signal regulation in cells, that is, local competition for ligands between/among receptors with quantitatively different abilities to activate their common downstream pathways. This regulatory mechanism may be integrated in the process of interpreting extracellular signals in many biological events.
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